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Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP
and the SH in Thessaloniki, Greece
Classiﬁcation and proper treatment of extranodal
lymphoma is hindered by the diversity of lymphoma
types and the relative rarity of many of these tumour
types. In order to review controversial issues in
extranodal lymphoma diagnosis, a joint Workshop of
the European Haematopathology Association (EAHP)
and the Society for Hematopathology (SH) was held,
where 99 selected cases were reviewed and discussed.
This Workshop summary is focused on the most
controversial aspect of cutaneous B-cell lymphoma,
other extranodal B-cell lymphomas, plasmablastic
lymphoma and anaplastic large-cell lymphoma in
extranodal sites, and makes practical recommendations
about diagnosis and therapeutic approaches.
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Extranodal lymphoma diagnosis, classiﬁcation and
appropriatetreatmentareafrequentchallengeinroutine
lymphoma diagnosis, due to the signiﬁcant variety of
morphologies, molecular alterations and clinical presen-
tations that the term extranodal lymphoma encom-
passes. Thus, B- and T-cell lymphoma diagnosed at
extranodal sites may imply quite different risks for the
patient and require diverse therapeutic approaches.
A workshop was organized by the European Associ-
ation of Haematopathology (EAHP) and the Society for
Hematopathology (SH) during the XII Meeting of the
EAHP held in Greece in October 2004, in order to
deﬁne better the single entities included within the
spectrum of extranodal B- and T-cell lymphoma.
Ninety-nine cases were received and reviewed by a
panel of experienced haematologists. The Workshop
provided a valuable opportunity for an open discussion
between case submitters, the panel and other partici-
pants, whose main conclusions are summarized in the
current report.
Highlights of cutaneous lymphomas
Several lymphoma cases were presented highlighting
the usefulness of the recently published new consensus
World Health Organization-European Organization for
the Research and Treatment of Cancer (WHO-EORTC)
classiﬁcation of cutaneous lymphoma.
1 In the group of
primary cutaneous B-cell lymphomas (Table 1), the
following clinicopathological entities could be differen-
tiated: (i) primary cutaneous marginal zone B-cell
lymphoma, (ii) primary cutaneous follicle centre lym-
phoma (PCFCL), (iii) primary cutaneous diffuse large
B-cell lymphoma, leg type (PCLBCL leg-type), and
(iv) primary cutaneous large B-cell lymphoma, other,
in which primary cutaneous intravascular B-cell lym-
phoma is included. Since the classiﬁcation of primary
cutaneous large B-cell has been the subject of much
debate in the past, they are discussed here in more
detail. The basis for these new insights is that the
available and new data indicate that PCFCL and
PCLBCL, leg-type are indeed different clinicopatholog-
ical entities with their own immunophenotypical and
genotypic characteristics.
PCFCL is deﬁned as a tumour of neoplastic follicle
centre cells, usually a mixture of centrocytes (small and
large cleaved follicle centre cells) and variable numbers
of centroblasts (large non-cleaved follicle centre cells
with prominent nucleoli), which generally present on
the head or trunk. The growth pattern may be
follicular, follicular and diffuse or diffuse, i.e. a con-
tinuum without distinct categories or grades. Lymph-
omas with a diffuse growth pattern and a monotonous
proliferation of centroblasts and immunoblasts are,
irrespective of site, excluded and are classiﬁed as
PCLBCL, leg-type or, rarely, primary cutaneous large
B-cell lymphoma, other. However lymphomas with
these histological characteristics occur only rarely on
head and trunk.
Irrespective of the growth pattern (follicular or
diffuse), the number of blast cells or the presence of
either localized or multifocal skin disease, these PCFCLs
have an excellent prognosis with a 5-year survival of
over 95%. A recent study suggests that strong expres-
sion of Bcl-2 in the subset of PCFCL with a diffuse large
cell histology and primary cutaneous large B-cell
lymphoma, other, is associated with a more unfavour-
able prognosis.
2 However, it is important to exclude
systemic B-cell lymphoma when Bcl-2 expression is
found in PCFCL (Figure 1).
PCLBCL, leg type, shows predominance or conﬂuent
sheets of centroblasts and immunoblasts (round cells),
characteristically presenting with skin lesions on the
(lower) legs. Uncommonly, skin lesions with a similar
Table 1. B-cell cutaneous lymphoma. Learning from the
Workshop
1 Primary cutaneous follicle centre lymphoma and
primary cutaneous diffuse large B-cell lymphoma,
leg type, are indeed different clinicopathological
entities with their own immunophenotypic and
genotypic characteristics
2 Primary cutaneous follicle centre lymphoma is
a tumour of neoplastic follicle centre cells, which
generally present on the head or trunk. The growth
pattern may be follicular, follicular and diffuse
or diffuse
3 Lymphomas with a diffuse growth pattern and a
monotonous proliferation of centroblasts and
immunoblasts are, irrespective of the site of the
disease, classiﬁed as primary cutaneous diffuse
large B-cell lymphoma, leg type, or rarely primary
cutaneous large B-cell lymphoma, other
4 The term primary cutaneous large B-cell lymphoma,
other, refers to rare cases of large B-cell lymphoma
arising in the skin, which do not belong to the
group of primary cutaneous diffuse large B-cell
lymphomas, leg type, or the group of primary
cutaneous follicle centre lymphomas. These cases
include morphological variants of diffuse large
B-cell lymphoma, such as anaplastic or
plasmablastic subtypes or T-cell ⁄ histiocyte-rich
large B-cell lymphoma
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than the legs.
The 5-year survival of PCLBCL, leg type, is 55% in
the Dutch and Austrian cutaneous lymphoma regis-
tries. It affects predominantly elderly female patients.
PCLBCL, leg type, on the leg has a worse prognosis
compared with PCLBCL, leg type, presenting at other
sites.
3 The presence of multiple skin lesions at diagnosis
is a signiﬁcant adverse risk factor. In a recent study,
patients presenting with a single skin tumour on one
leg had a disease-related 5-year survival of 100%,
whereas patients presenting with multiple skin lesions
on one or both legs had a disease-related 5-year
survival of 45% and 36%, respectively.
4,5
The phenotype of PCFCL is that of a B-cell (CD20+,
CD79a+), Bcl-6+, Bcl-2– or faint +, Mum-1 ⁄ IRF4–,
CD10– ⁄ + diffuse lesion mostly negative. The t(14;18)
often seen in systemic follicular lymphomas and part
of systemic diffuse large B-cell lymphoma (DLBCL) is
absent.
6 In contrast, PCLBCL, leg type, has a B-cell
phenotype (CD20+, CD79a+), but is MUM-1 ⁄ IRF4+
and FOX-P1+. Bcl-6 is expressed by most cases,
whereas CD10 staining is generally absent. Bcl-2 is
positive, although t(14;18) is absent.
7–11
Chromosomal imbalances have been identiﬁed by
comparative genomic hybridization (CGH) analysis in a
minority of PCFCLs, but a consistent pattern has not
yet emerged. In a recent study using interphase
ﬂuorescence in situ hybridization, no evidence of
translocations involving IgH, myc or Bcl-6 loci were
found.
12 PCFCLs have the gene expression proﬁle of
germinal centre-like large B-cell lymphomas.
13
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Figure 1. a–f, Primary cutaneous follicle centre lymphoma. a, Nodular pattern. b, Centroblastic predominance. c, CD20. d, CD10. e, Bcl-2.
f, Ki67. g–j, Primary cutaneous diffuse large B-cell lymphoma, leg type. g,h, morphology, H&E. i, CD20. j, Ki67. Cases contributed by C. Girardet
(A6) and R. S. Robertorye (A8).
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onstrated translocations involving myc, Bcl-6 and IgH
genes, but not in patients with a PCFCL with a diffuse
inﬁltration of large centrocytes and suggest that
PCLBCL, leg type, has an activated B-cell gene expres-
sion proﬁle.
13–15 Inactivation of p15 and p16 tumour
suppressor genes by promotor hypermethylation has
been detected in both PCFCL and PCLBCL, leg type.
8
PCLBCL, other, refers to rare cases of large B-cell
lymphomas arising in the skin, which do not belong to
the group of PCLBCL, leg type, or the group of PCFCL.
1
These cases include morphological variants of DLBCL,
such as anaplastic or plasmablastic subtypes or
T-cell ⁄ histiocyte-rich large B-cell lymphomas. Such
cases are generally a skin manifestation of a systemic
lymphoma. Rare cases of primary cutaneous T-cell ⁄
histiocyte-rich B-cell lymphoma, characterized by the
presence of large scattered B cells in a background of
numerous reactive T cells, have been reported. Clinic-
ally, they show similarities to the groups of PCFCL and
primary cutaneous marginal zone lymphoma (PCMZL).
These lymphomas commonly present with skin lesions
onthehead,thetrunkortheextremities,andmayinfact
represent an exaggerated T-cell inﬁltrate in association
with other forms of cutaneous B-cell lymphoma (CBCL).
Unlike their nodal counterparts, they appear to have an
excellent prognosis. In addition, rare cases of primary
cutaneous intravascular large B-cell lymphoma may be
included in the category of PCLBCL, other.
In the group of cutaneous T-cell lymphoma, primary
cutaneous lymphomas (CTCL) other than mycosis
fungoides, Sezary syndrome and primary cutaneous
CD30+ lymphoproliferative diseases, which constitute
about 10% of all CTCL, have been classiﬁed. With few
exceptions, these lymphomas are clinically aggressive.
Cases with a favourable prognosis are restricted to the
provisional entity of small ⁄ medium-sized pleomorphic
CTCL with a CD4+ T-cell phenotype that presents with
localized disease.
16 One change from prior classiﬁca-
tions was prompted by recent studies showing clini-
cal, histological and immunophenotypical differences
between cases of subcutaneous panniculitic-like T-cell
lymphoma (SPLTCL) with an a ⁄ b T-cell phenotype and
those with a c ⁄ d T-cell phenotype, suggesting that
these may represent different entities.
17 Whereas
SPLTCL with an a ⁄ b T-cell phenotype are homogen-
eous with a rather indolent clinical behaviour in many
patients, SPLTCL with a c ⁄ d T-cell phenotype overlaps
with other types of c ⁄ d+T ⁄ natural killer (NK)-cell
lymphoma and invariably runs a very aggressive
clinical course. It was therefore suggested that the
term SPLTCL be restricted to SPLTCL with an a ⁄ b
T-cell phenotype. Three disorders, previously included
in the broad group of post-transplant lymphoprolifer-
ative disorder (PTLD), unspeciﬁed in the WHO classi-
ﬁcation, are proposed as provisional entities. These
include aggressive epidermotropic CD8+ CTCL, cuta-
neous c ⁄ d T-cell lymphoma (including cases formerly
diagnosed as SPLTCL with a c ⁄ d phenotype) and
primary cutaneous small–medium CD4+ T-cell lym-
phoma. In the WHO-EORTC classiﬁcation the term
PTL, unspeciﬁed, is maintained for remaining cases
that do not ﬁt into either of these provisional entities.
Plasmacytoid dendritic cell tumours
Plasmacytoid dendritic cell tumours are composed of a
monotonous proliferation of cells with lymphoblast-like
morphology and expression of CD4 and CD56. Because
of this immunophenotype it was initially believed that
these tumours are derived from NK cells and therefore
were categorized in the WHO classiﬁcation as blastic
NK-cell lymphomas. With the availability of new
antibodies it could be demonstrated that the cells of
this tumour type resemble immunophenotypically cells
that were ﬁrst described under the term ‘lymphoblasts’.
These cells were renamed several times according to
the features subsequently discovered: T-associated
plasma cells, plasmacytoid T cells, plasmacytoid mono-
cytes and ﬁnally plasmacytoid dendritic cells. The
immunophenotype of these cells is unique in that it is
distinct from all known lymphoid and myeloid cell
subsets (see Table 2).
It was the elucidation of the function of the cells
under discussion which clariﬁed their real nature. It
was found that these cells have the functional proﬁle of
dendritic cells in that they secrete large amounts of
interferon (IFN)-a ⁄ b, express TLR-7 and TLR-9, and
promote the function of NK, B and T cells as well of
myeloid dendritic cells.
18
Therefore, an appropriate name for these cells is
‘plasmacytoid dendritic cells’. Immunologists also call
these cells ‘interferon-producing cells’. Since they are
not the only cells which produce IFN and since the latter
term ignores the other features of these cells, the
Workshop board recommended use of the term ‘plasma-
cytoid dendritic cells’.
Plasmacytoid dendritic cells directly regulate the
functional activity of T cells by these functions and thus
link innate and adaptive immune responses. Thus,
plasmacytoid dendritic cells obviously carry at least
parts of the ‘evolutionary immunological memory’,
which is important for organisms to be protected by a
ﬁrst-line, immediately effective defence system.
The published immunophenotype of neoplasms of
plasmacytoid dendritic cells is nearly identical to that of
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nodes (Table 2). Among the neoplasms submitted to
the Workshop there were seven cases which had
exactly the immunophenotype of plasmacytoid dend-
ritic cell tumours as listed in Table 2. All seven cases
also displayed the typical histopathological features of
this tumour category, which can be summarized as
follows:
• Immature, lymphoblast-like cytology.
• Agranular cytoplasm.
• Cytoplasm full of microvesicles.
• Inﬁltration of the dermis,
• But consistent sparing of the epidermis.
• Involvement of lymph nodes in the para ⁄ interfolli-
cular areas.
The diagnostic separation of plasmacytoid dendritic
cell tumours from other haematopoietic malignancies
is clinically relevant, since the clinical characteristics
and clinical outcome, including response to current
treatment modalities ,differ from those of lymphomas
and myeloid proliferative diseases. Plasmacytoid dend-
ritic cell tumours usually affect elderly patients, mani-
fest in the skin and bone marrow, evolve frequently
to an overt leukaemia associated with an aggressive
course and death within 3 years despite initial response
to therapy. This adverse disease course requires the
development of new therapeutic strategies.
Thyroid lymphoma
Lymphomas of the thyroid are rare. They make up no
more than 5% of thyroid neoplasms, no more than
2.5% of lymphomas in general and only up to 7% of
extranodal lymphomas.
19,20 About 50–80% of primary
thyroid lymphomas are of diffuse large B-cell (DLBCL)
type and, in most series, about 20–30% are extranodal
marginal zone B-cell lymphomas (MZBCL) of mucosa-
associated lymphoid tissue type (MALT lymph-
oma)
19,21–23 (Swerdlow, unpublished). A minority of
the DLBCLs also include a MALT lymphoma compo-
nent. Although in the past many thyroid lymphomas
were thought to be of follicular centre cell type,
24,25
with the recognition of MALT lymphomas
25,26 and the
segregation of DLBCL, the more recent series have
reported no more than 12% follicular lymphomas (FL).
Some series of primary thyroid lymphomas have also
included rare cases of plasmacytoma (which some
would argue represents a MALT lymphoma),
25,27
Burkitt lymphoma, small lymphocytic lymphoma,
anaplastic large cell lymphoma and peripheral T-cell
lymphoma. At least in some series, the vast majority of
thyroid lymphomas are associated with lymphocytic ⁄
Hashimoto’s thyroiditis. Primary lymphomas of the
thyroid show a female predominance and occur in
adults with a mean age in the 60s. About 90% of cases
are stage IE or IIE, although some report a greater
proportion of higher stage cases. The MALT lymph-
omas are considered indolent neoplasms with disease-
speciﬁc and even overall 5-year survivals from 60 to
100% whereas patients with DLBCL are reported to
have a 40–70% 5-year survival, whether or not they
have a MALT component.
19,22,23,28 Advanced age or
stage as well as a diagnosis of DLBCL versus MALT
lymphoma are recurrently reported adverse prognostic
indicators.
19,22,23,28
The Workshop included ﬁve thyroid lymphomas,
none of which was of MALT type. These cases raised
a number of both practical and biological issues
(Table 3). First, what is a primary thyroid lymphoma?
Deﬁnitions have included a dominant thyroid lesion,
primary complaint related to the thyroid, thyroid
involvement at diagnosis or a history of Hashimoto’s
thyroiditis. Series of secondary lymphomas of the
thyroid will include a much wider variety of lymph-
omas with a smaller proportion of MALT lymphomas
and DLBCL.
21 Nevertheless, one must recognize, as
seen in this Workshop, that uncommon lymphomas
Table 2. Comparison of the immunophenotype of normal
and tumoral plasmacytoid dendritic cells (PDC)
Marker
PDC in reactive
lymph nodes
PDC tumours
N ¼ 7
CD4 + +
CD56 – ⁄ (+) +
HLA-DR + +
CD43 + +
TCL1 – ⁄ (+) +
CD123 + +
CD45RA + +
CD68 + + ⁄ –
Granzyme B – + ⁄ –
TdT – + ⁄ –
Perforin – –
CD45RO – –
Myeloperoxidase – –
CD34 – –
CD20, CD3 – –
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Workshop, rarely even peripheral T-cell lymphomas
can be localized to the thyroid.
29,30 Like many other
primary thyroid lymphomas, these also appear to be
associated with Hashimoto’s thyroiditis. The Workshop
case of a mantle cell lymphoma in the thyroid
engendered a discussion about the criteria for designa-
ting a disseminated lymphoma as being of primary
extranodal type, a label of uncertain clinical signiﬁ-
cance in this setting. Arguments put forward to support
a primary designation included a markedly enlarged
thyroid, apparent thyroiditis and simultaneous presen-
tation of the extrathyroidal disease. The possibility that
lymphomas might be more likely to home to a thyroid
that has thyroiditis could also be considered.
The second and probably most contentious issue
concerned the criteria for distinguishing FL of the
thyroid (with lymphoepithelial lesions) from a MALT
lymphoma (with follicular colonization) and led to a
broader discussion of whether extranodal FLs are a
unique entity. This issue was raised with the presen-
tation of a case that was representative of a study
subsequently published in abstract form (Figure 2).
31
These authors report a series of 22 patients with FL
presenting in the thyroid. Many but not all were
CD10+ (16 ⁄ 22), all were Bcl-6+ but almost half lacked
Bcl-2 expression (9 ⁄ 22) and only half of those studied
had an IGH ⁄ BCL2 translocation. BCL6 translocations
were present in 2 ⁄ 12 cases. Morphologically, similar-
ities to MALT lymphomas reportedly included a marked
interfollicular expansion and prominent lymphoepit-
helial lesions. They noted a correlation between the
lack of Bcl-2 protein and gene translocation, stage IE
disease and a good clinical outcome, suggesting that
these are the cases that may be the truly primary
thyroid FL. This constellation of ﬁndings, together with
the morphological features, led some to believe that at
least a subset of these lymphomas were, in fact, more
like MALT lymphomas. However, while a lack of
CD10 may be unusual in other extranodal FL,
32
Bcl-6 expression is not expected in MALT lymphomas
and absent Bcl-2 expression and especially absent
IGH ⁄ BCL2 translocations are features more commonly
seen in cutaneous and certain other extranodal FL
compared with nodal FL.
12,32 This is in contrast to
primary FL of the gastrointestinal tract, which is most
common in the duodenum and is usually Bcl-2+.
33,34
Also relevant is the observation that CD10 expression is
not necessarily pathognomonic of a follicular centre
cell lymphoma. There are very rare CD10+ MZBCLs,
including a reported thyroid MZBCL
35 and a Bcl-6–
nodal MZBCL.
36 Although no deﬁnite consensus was
reached, it should be noted that it is already well
documented that classic CD10+, IGH ⁄ BCL2+ extra-
nodal FL can closely resemble MALT lymphomas.
37 At
a minimum, while the actual frequency of bona ﬁde FL
arising in the thyroid remains to be determined, it
clearly does occur. Furthermore, it was brieﬂy dis-
cussed that the thyroid DLBCL presented at the
workshop was CD10+, as were almost half of the
DLBCLs of the thyroid we had reviewed, with 1 ⁄ 2
tested even demonstrating an IGH ⁄ BCL2 translocation.
This suggests that a subset of DLBCLs of the thyroid is
also of germinal centre cell type, inferring that it would
not be unexpected to ﬁnd FL at the same site.
Third, the Workshop cases highlighted the observa-
tion that lymphoepithelial lesions (LELs) are not
pathognomonic of a MALT lymphoma. Aside from
LELs being a part of Hashimoto’s thyroiditis, morpho-
logically identiﬁed LELs were present in varied B-cell
and even non-B-cell lymphomas. LEL demonstrating
thyroid follicles stuffed with lymphoid cells (‘MALT
ball’ LEL
19) as well as large LELs are reported to be
characteristic of those found in MALT lymph-
Table 3. Thyroid lymphoma, pointers from the Workshop
Most common thyroid lymphoma is diffuse large
B-cell lymphoma, less often MALT lymphoma, some
follicular lymphomas, rarely other types (see below)
Designation of a disseminated thyroid lymphoma as
‘primary’ may be problematic but it is not of known
clinical signiﬁcance
Primary follicular lymphomas occur in the thyroid;
however, they are currently probably under-recognized
as some cases share many morphological,
immunophenotypic and genotypic features with
MALT lymphomas. Like the situation with some other
types of extranodal FL, this distinguishes a subset of
these cases from many nodal FL and suggests that they
are a part of a separate and distinct entity; however,
it also makes categorization of some individual
cases controversial
Lymphoepithelial lesions occur in thyroiditis and varied
types of thyroid lymphomas, i.e. they are NOT
pathognomonic or even highly suggestive of a
MALT lymphoma
Although controversial and in contrast to the situation in
the salivary gland, documentation of a major clonal
B-cell population in the thyroid strongly favours
a B-cell lymphoma over an autoimmune disorder
The newly described FOXP1 ⁄ IGH translocation is important
in thyroid MALT lymphomas
MALT, Mucosa-associated lymphoid tissue; FL, follicular
lymphoma.
486 E Campo et al.
  2006 The Authors. Journal compilation   2006 Blackwell Publishing Ltd, Histopathology, 48, 481–504.omas;
19,20,38 however, morphologically similar-appear-
ing LELs are described in some T-cell neoplasms.
30
MALT lymphomas also demonstrate LELs that are more
like those seen in the salivary gland without intra-
acinar balls of neoplastic lymphoid cells. While ﬁnding
a paucity of B-cells will often help exclude the type of
LEL seen in MALT lymphomas, the case of Hodgkin’s
lymphoma had LEL that included areas with numerous
B cells (Figure 3). In addition, although many of the
LELs in Hashimoto’s thyroiditis are associated predom-
inantly with T cells, rare small B-cell LELs were
reported to occur in 13 ⁄ 40 cases in one series and
another smaller series describes predominantly B cells
in the LELs of even ‘early’ Hashimoto’s thyroidi-
tis.
20,38,39 It should also be remembered that LELs in
a DLBCL do not make it of ‘MALT type’.
Given that Hashimoto’s thyroiditis, which can dem-
onstrate a very dense lymphoplasmacytic inﬁltrate, and
LELs can be very difﬁcult to distinguish from MALT (or
other) lymphomas, the question was raised as to
whether, unlike in the salivary gland,
40–42 genotypic
studies can be used to distinguish thyroiditis with LEL
from a MALT lymphoma. While the literature is not
consistent, Hsi et al. and others have reported no
CD10
a b
c
d
Figure 2. Follicular lymphoma of the thyroid. a, The thyroid in this 70-year-old male is extensively inﬁltrated by numerous lymphoid follicles
with relatively homogeneous-appearing follicular ⁄ germinal centres. b, The interfollicular regions (left) adjacent to the neoplastic-appearing
follicle demonstrate many small lymphocytes and prominent lymphoepithelial lesions. c, There are numerous small angulated lymphocytes with
pale cytoplasm but only infrequent centroblasts in this follicular ⁄ germinal centre. (a–c, haematoxylin and eosin.) d, There are only scattered
cells staining distinctly for CD10. Weak positivity was described in the case presentation. (CD10 immunostain with haematoxylin counterstain.)
Other immunophenotypic studies were reported to show the following: CD20+, IgM–, IgD–, Bcl-6+, Bcl-2– and 50% Ki67 staining in the
follicular structures. Polymerase chain reaction (PCR) studies did not demonstrate a clonal IGH rearrangement and neither PCR nor cytogenetic
ﬂuorescence in situ hybridization studies showed an IGH ⁄ BCL2 translocation. Case contributed by E. Navratil, A. Dogan, P. Isaacson.
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38,43
Of interest, in a recent study reporting ‘clonal B cell
populations in a minority of patients with Hashimoto’s
thyroiditis’, the polymerase chain reaction (PCR)-iden-
tiﬁed clones were not only associated with a polyclonal
smear but were not reproducible when PCR was
performed on either deeper sections in the same block
or using another block.
44
Finally, although not addressed in this session, the
subject of chromosomal abnormalities in MALT
lymphomas was covered.
45 It is of interest that the
newest chromosomal translocation to be associated
with MALT lymphomas, t(3;14)(p14.1;q32) involving
IGH and FOXP1, has been reported in 10% of MALT
lymphomas in general, but has been found in 3 ⁄ 6
cases in the thyroid.
46
Lymphomas at other extranodal sites
A total of 21 cases of mostly B-cell lymphomas restricted
to unusual sites of involvement (bone, brain, lung,
salivary glands, tonsil, testis, prostate, breast, ovary and
uterus) were included. The main criteria and reasons
for submitting a case were histological classiﬁcation,
uncommon location, differential diagnosis between
lymphomatous and non-lymphomatous lesions, as well
as discrimination of subgroups and entities with histo-
logical, clinical and prognostic importance.
Primary small lymphocytic lymphomas of the CNS
are very rare. Especially, primary lymphoplasmacytic
lymphomas of the brain are extemely uncommon
(Figure 4). In such cases secondary inﬁltrations by
systemic lymphoplasmacytic lymphoma, the so-called
Bing and Neel syndrome, as well as the possibility of
meningeal MALT-type lymphoma of the CNS must be
considered seriously.
47,48
Osteolytic and tumorous bone lesions occur second-
arily in hairy cell leukaemia.
49,50 Their manifestation
before the development of the classical haematological
picture of hairy cell leukaemia is extraordinarily rare.
Immunohistochemical positivity of neoplastic cells for
cyclin D1 and annexin 1
50 could be helpful for the
differential diagnosis of such cases of hairy cell leuk-
aemia from other types of bone marrow lymphomas.
Burkitt lymphomas restricted to one organ such as
the liver, prostate, testis and uterus are very rare.
50–53
Their accurate diagnosis based on morphological,
immunohistochemical and molecular criteria is neces-
sary because they may have a rather favourable
outcome after appropriate therapy.
51,53
Primary extranodal, extracutaneous FLs occur
rather infrequently.
54–58 In general, with the possible
exception of gastrointestinal FL, these lymphomas have
microscopic, immunohistochemical and molecular fea-
tures different from the nodal FL, being in most cases
Bcl-2– and t(14;18)–.
56,59–62 One of the cases discussed
in the Workshop illustrated a recurrence in the salivary
gland of a case initially diagnosed as cutaneous
follicular centre lymphoma, which could point to the
existence of some common features for most of these
extranodal FLs. Nevertheless, some extranodal locali-
zations need to be considered as separate subgroups,
as happens, for example, with the testicular FLs of
childhood, which seem to have an excellent outcome
AE1-AE3/CD20  AE1-AE3/CD3 
Figure 3. Classical Hodgkin lymphoma in thyroid. These double immunostains with the AE1 ⁄ AE3 cytokeratin stain in black demonstrate that
the lymphoepithelial lesions present in this case included some with many B cells (CD20 immunostain in red ⁄ brown on the left) and some with
many T cells (CD3 immunostain in red ⁄ brown on the right). (Double immunostains with haematoxylin counterstain.) Case contributed by
M. Vornanen.
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55,61). A few
similar cases may also occur in adults (Figure 5).
Large B-cell lymphomas of terminally
differentiated B cells
Plasmablastic lymphoma is considered a variant of
DLBCL in the WHO classiﬁcation. This tumour was
initially described as a DLBCL with immunoblastic or
large B cells and a phenotype resembling the terminally
differentiated B cell, characterized by negative or weak
expression of mature B-cell markers (CD20) and
positivity for plasma cell-associated antigens (CD38,
CD138).
63 The tumours were mainly diagnosed in
patients infected with the human immunodeﬁciency
virus (HIV) and they presented commonly in the
mucosa of the oral cavity. The clinical behaviour was
aggressive with poor response to therapy and short
survival. In spite of this initial deﬁnition, the term
‘plasmablastic’ has been applied in different situations
to describe morphological or immunophenotypic fea-
tures in the context of other large B-cell or plasma cell
neoplasms. In addition, several studies have now
recognized other lymphomas with similar morphologi-
cal and phenotypic plasmablastic features but with
diverse clinical and molecular characteristics suggest-
ing that they may correspond to different disease
entities (Table 3). Several cases submitted to the
Workshop illustrated the diversity of these tumours
and provide new insights into their clinical and
pathological characteristics.
plasmablastic lymphoma
Plasmablastic lymphomas were initially recognized as
proliferations of large B cells with immunoblastic
morphology and plasma cell immunophenotype. The
cells had a cohesive pattern of growth and a
CD138
Kappa
HE
Figure 4. Lymphoplasmacytic lymphoma, primary in brain. Case contributed by E. Hsi (case B5).
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terms of size and cytoplasmic characteristics. The
tumours presented in the oral cavity and were mainly
diagnoses in HIV+ patients.
63 Three cases presented in
the Workshop were diagnosed as plasmablastic lym-
phoma in HIV+ patients. However, these three cases
had morphological and clinical differences from the
original description indicating that the spectrum of
these lymphomas may be broader than initially con-
sidered. The three tumours were morphologically
characterized by a proliferation of immunoblasts and
plasmablasts that were CD20– and CD79a– but positive
for plasma cell-associated antigens and Epstein–Barr
virus (EBV) with a type I latency pattern. However, in
contrast to the original description of the plasmablastic
lymphoma of the oral cavity, they contained also a
range of cells with plasmacytic differentiation similar to
the subtype recently recognized by Colomo et al.a s
plasmablastic lymphoma with plasmacytic differenti-
ation
64 (Figure 6). These tumours presented in extra-
nodal sites other than oral mucosa (rectal mucosa 2,
testis 1). One of the cases had a low M-spike and bone
marrow involvement. This case illustrates the recent
ﬁndings by Teruya-Feldstein et al. indicating that
plasmablastic lymphoma may present with extensive
bone involvement and a minimal M-component.
65
However, the clinical and pathological characteristics
were not consistent with multiple myeloma (MM). The
behaviour of the plasmablastic lymphoma is usually
aggressive. However, recent reports suggest that
patients treated now with highly active antiretroviral
therapy (HAART) and improvement of their CD4
counts may have a better outcome than the cases
initially reported.
65,66
primary effusion lymphomas and extra-
cavitary primary effusion lymphoma variant
Primary effusion lymphoma (PEL) is a well-recognized
entity in immunosuppressed patients associated with
CD20 
BCL6 
Figure 5. Testicular follicular lymphoma, grade IIIa, t(14;18)–. Case contributed by C. Bacon and A. Dogan (case G6).
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ized by a proliferation of large pleomorphic B cells that
lack expression of B-cell markers and immunoglobulin
but commonly express plasma cell-associated antigens
and CD30. These tumours usually present as effusion
lymphomas with no involvement of tissues.
67 How-
ever, some patients may develop a solid tissue mass in
the evolution of the disease or, alternatively, may
present with a tissue tumour mass and subsequently
develop a cavitary lymphomatous effusion. The extra-
cavitary dissemination usually includes lymph nodes,
lung, skin, gastrointestinal tract and occasionally oral
mucosa and larynx.
68,69 One of the cases presented in
the Workshop illustrated this presentation as a HHV-
8+ nodal large cell lymphoma with plasmablastic
features that subsequently developed a gastrointestinal
mass and tumoral ascites. Several studies have
recognized also a pure extracavitary variant of PEL
in which the tumour presents as a solid tissue mass
without evidence of malignant effusions.
68,70 This
variant has similar morphological, immunophenotypic
and molecular characteristics to PEL, suggesting that
they belong to the same entity. The extracavitary
presentation of these tumours also involves similar
sites such as skin, gastrointestinal tract and lymph
nodes. However, these solid tumours have some
phenotypic peculiarities including a slightly more
frequent expression of mature B-cell markers (CD20)
and immunoglobulins, occasional expression of T-cell-
associated markers and less EBV positivity. Interest-
ingly, patients with solid variants of PEL may have
fewer opportunistic infections and better survival than
those with classical PEL. However, similar to the
recent observation in plasmablastic lymphoma,
65 this
better outcome may be due in part to the treatment of
HIV+ patients with HAART leading to better control
of the HIV infection and improvement of the CD4
counts.
68
extramedullary plasmablastic tumours
secondary to plasma cell neoplasms
Plasmablastic lymphomas, particularly with plasma-
cytic differentiation, are morphologically and pheno-
typically similar to extramedullary large cell
transformation of plasma cell neoplasms. The distinc-
tion between these neoplasms may be difﬁcult if not
impossible without clinical correlation. Most transfor-
mations of extramedullary plasmacytomas or extra-
medullary dissemination of MM occur as secondary
evolution of these diseases several years after diagnosis
but in some cases extramedullary involvement may
occur simultaneously with the initial diagnosis of
MM.
65,71 One of the cases submitted to the Workshop
was an extranodal large B-cell neoplasm with plasma-
blastic features which 2 years later, and after a com-
plete remission with chemotherapy, progressed to an
overt MM, illustrating the difﬁculties in the differential
diagnosis between plasmablastic lymphoma and high-
grade plasma cell neoplasms. Clinically, extramedullary
plasmablastic tumours secondary to plasma cell neo-
plasms occur in immunocompetent patients, whereas
plasmablastic lymphomas are usually associated with
immunosuppression. Phenotypically, both types of
tumours are relatively similar, although CD56 expres-
sion may be slightly more common in the ﬁrst group
and cyclin D1 positivity is detected only in MM
patients.
65,71,72 EBV infection is frequently present
in plasmablastic lymphoma and usually negative in
plasma cell tumours. However, occasional nasopharyn-
geal plasmacytomas and derived plasmablastic lymph-
omas may be EBV+.
65
MYELOMA HIV-PLASMABLASTIC PEL
a b c
Figure 6. a, Extramedulary involvement by multiple myeloma. Case A11 contributed by F. Fend. b, Plasmablastic lymphoma with plasmacytic
differentiation in a HIV+ patient. Case C12 contributed by J. Teruya-Feldstein. c, Primary effusion lymphoma presenting as a solid tumour.
The tumour was positive for HHV8. Case C7 contributed by A. Dogan.
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plasmablastic features
In addition to the previous types of tumours, other
lymphomas may have some features like those of
plasmablastic lymphoma yet they may represent dif-
ferent entities. Particularly, DLBCL expressing anaplas-
tic lymphoma kinase (ALK) protein may correspond to
a distinct disease in this spectrum of neoplasms.
73
These tumours are usually nodal and present in young
immunocompetent patients. Morphologically, they
are composed of monomorphic proliferations of large
B cells, EBV–, with a plasmablastic phenotype and
frequent expression and secretion of IgA. Similar to
anaplastic large-cell lymphoma, ALK expression is due
to ALK rearrangements, particularly with clathrin or
less frequently with nucleophosmin.
74,75 The beha-
viour is aggressive and most patients die of the disease
in a short period of time. Another tumour in this
spectrum is the HHV-8+ large B-cell lymphoma emer-
ging in the context of multicentric Castleman’s dis-
ease.
76 This tumour has been named plasmablastic
lymphoma because of the immunoblastic ⁄ plasmablas-
tic appearance of the cells. However, the cells strongly
express CD20, a marker uncommon in the late stage of
B-cell differentiation. Occasional aggressive DLBCL
shows marked secretory differentiation with abundant
basophilic cytoplasm, a paranuclear hof and marked
cytoplasmic immunoglobulin expression. However,
these tumours are strongly CD20+, EBV– and occur
in immunocompetent patients.
77 These lymphomas, as
well as the EBV+ DLBCL associated with pyothorax, are
probably variants of DLBCL at a more mature ter-
minal stage of differentiation than plasmablastic
lymphoma (Table 4).
78
In summary, the cases presented in the Workshop in
the plasmablastic lymphoma session illustrate the
clinical and pathological heterogeneity of these
lymphomas. These observations are concordant with
several recent publications suggesting that large B-cell
lymphomas with features of terminally differentiated B
cells are different from conventional DLBCL and most
probably include different disease entities that should
be individually recognized.
Other lymphoproliferative disorders in
immunocompromised patients and
EBV-related lymphomas
The WHO classiﬁcation of tumours of haematopoietic
and lymphoid tissues includes immunodeﬁciency-
associated lymphoproliferative disorders (IDA-LPDs)
79
which are grouped in four main categories: (i) associ-
ated with primary immune disorders (PID), (ii) associ-
ated with HIV infection, (iii) post-transplant and
(iv) methotrexate-associated.
Thirteen examples of extranodal lymphoid prolifer-
ation in immunosuppressed patients were submitted to
the Workshop, including cases of PTLD; patients with
autoimmune disorders treated with methotrexate;
patients with a previous lymphoma treated with
chemotherapy, and associated with EBV infection
without clinical evidence of immunosuppression.
HIV+ cases have already been discussed in the
plasmablastic lymphoma section.
These cases illustrate the variety of clinical situations
in which IDA-LPDs may occur, which includes not only
the well-known conditions, but autoimmune disorders,
methotrexate or other immunosuppressive treatment,
haematological neoplasms and newly emerging phe-
nomena, such as senile LPD,
80 which may not yet be
recognized. In fact, LPDs may be related to one or more
underlying viral infections, such as those sustained
by EBV, in which there is no recognized cause for
immunosuppression.
The IDA-LPDs presented at the Workshop showed
heterogeneous pathological manifestations. They inclu-
ded overt malignant lymphomas (of peripheral B- and
T-cell derivation), polymorphic (polyclonal and mono-
clonal) proliferations and lesions of uncertain biological
Table 4. Diffuse large B-cell lymphomas (DLBCL) with ter-
minally differentiated B-cell phenotype
Plasmablastic lymphomas (PBL)
Plasmablastic lymphoma of oral mucosa type
Plasmablastic lymphoma with plasmacytic differentiation
HHV-8-associated lymphomas
Plasmablastic lymphoma associated with multicentric
Castleman’s disease*
Primary effusion lymphoma (PEL)
Extracavitary variant of PEL
Extramedullary plasmablastic tumours secondary to plasma
cell neoplasms
Diffuse large B-cell lymphoma expressing ALK
Differential diagnosis*
Diffuse large B-cell lymphoma with secretory differentiation
Pyothorax-associated lymphoma
*These tumours express strong CD20 and therefore are
probably better designated as immunoblastic variants of
diffuse large B-cell lymphoma.
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in nodal disorders.
81 In particular, among the PTLDs
three cases showed plasmablastic ⁄ plasmacytic differ-
entiation similar to the previously discussed cases of
large B-cell lymphoma with plasmablastic features.
About half of the PTLD cases were EBV– and tended to
occur later than EBV+ ones. (Interestingly, one case
associated with methotrexate was a lymphoprolifera-
tive disorder with the morphological features of a
Hodgkin-like lesion according to the WHO classiﬁca-
tion, but the immunophenotype and very aggressive
clinical course indicated that it was a true malignant
Hodgkin’s lymphoma.)
Mucosa-associated lymphomas
Two major types of non-Hodgkin’s lymphomas primar-
ily present at mucosal sites: one is extranodal MZBCL of
mucosa-associated lymphoid tissue (MALT lymphoma)
which commonly arises in the stomach from mucosal
lymphoid tissue that is acquired usually as a reaction
to Helicobacter pylori and follows an indolent clinical
course; the other is represented by enteropathy-type
T-cell lymphoma (ETCL) derived from intestinal intra-
epithelial T cells often evolving as a consequence of
adult-onset coeliac disease with usually rapidly fatal
outcome. A third, albeit reactive process of the MALT,
termed atypical marginal zone hyperplasia of MALT,
was described most recently to occur in the tonsil or
appendix in childhood. All of these three conditions
were represented at the Workshop by at least one case
each and merit attention as outlined below. The main
focus was on extragastric MALT lymphoma, as gastric
cases have been excluded.
extragastric malt lymphoma
Primary extragastric MALT lymphoma preferentially
involves the ocular adnexa, salivary gland, skin, lung,
intestine, thyroid and breast
82–84 (Figure 7). Recent
evidence suggests that extragastric MALT lymphoma
may also be associated with infectious agents such as
CD20
CD21
CD3
KL1
ac d
e f b
Figure 7. Marginal zone B-cell lymphoma in the breast. a,b, Morphology. c, CD20. d, CD3. e, CD21. f, KL1. Case contributed by F. Gaillard (D12).
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psittaci in MALT lymphoma of the ocular adnexa, and
Campylobacter jejuni in a special form of intestinal
MALT lymphoma termed immunoproliferative small
intestinal disease (IPSID).
85–87 The pathogenic role of
these microbes in the development of the respective
MALT lymphoma appears, however, to be not as
straightforward as that of H. pylori.
88 In general our
knowledge of extragastric MALT lymphomas lags
somewhat behind that of gastric disease. Therefore
this summary concentrates on some general and some
new issues in extragastric MALT lymphomas.
Besides the most common sites, Workshop MALT
lymphoma cases also comprised unusual examples
such as tumours arising in the thymus, subcutaneous
tissue, dura and larynx, indicating that there is almost
no organ or tissue which, upon triggering by an
inﬂammatory response, cannot give rise to this type of
marginal zone B-cell-related neoplasia. Hence, the
histological appearance of MALT lymphoma is mark-
edly inﬂuenced by the local environment (mucosal
versus non-mucosal) and the underlying inﬂamma-
tory ⁄ autoimmune processes. Whereas the cytomor-
phology of the tumour cells may vary among MALT
lymphomas and even within the same tumour, ranging
from small lymphoid cells to centrocyte-like cells and
monocytoid cells, non-neoplastic germinal centres or
colonized remnants thereof are an almost constant,
site-independent ﬁnding.
82 At mucosal sites the fre-
quency of LELs, reﬂecting the interaction between
lymphoma cells and epithelial structures, depends
heavily on the site involved, i.e. they are invariably
present in MALT lymphomas of the thyroid, often seen
in salivary glands and lung, rarely encountered in the
ocular adnexa, particularly the lacrimal gland, intes-
tine and breast, and exceedingly rare to absent in
cutaneous MALT lymphomas. Importantly, LEL are
neither speciﬁc for MALT lymphoma nor required for
the diagnosis.
As MALT lymphoma derives from postgerminal
centre memory B cells, it is not surprising that
plasmacytic differentiation may occur in up to 30%
of extragastric MALT lymphomas and is very often
associated with serum paraproteinaemia.
89 Histologi-
cally, small groups or sheets of light chain restricted
lymphoplasmacytoid cells and ⁄ or plasma cells, usually
containing IgM, are part of the inﬁltrate, occasionally
showing intranuclear periodic acid–Schiff-positive
material (Dutcher bodies).
Differential diagnostic considerations include small
B-cell lymphocytic proliferations, mantle cell lym-
phoma and FL. Most cases are CD20+, CD5–, Bcl-6–,
CD10–, CD23–, and these cells often colonize reactive
germinal centres which display a disrupted network of
CD21+ follicular dendritic cells. Unfortunately, there is
no highly characteristic marker for MALT lymphoma,
such as cyclin D1 for mantle cell lymphoma. A few
cases have been reported to express CD5, some are
known to be CD43+, although the frequency of the
latter is probably lower than in gastric MALT lymph-
omas.
90 Nuclear Bcl-10 expression has been demon-
strated to be strong in t(1;14)(q22;q32)+ cases and
moderate in almost all t(11;18)(q21;q21)+ MALT
lymphomas.
83 In daily practice, however, the immuno-
histochemical detection of Bcl-10 expression cannot be
recommended as a reliable tool for the demonstration
of the t(11;18)(q21;q21).
The remarkable recent advances in genetics and
molecular biology in MALT lymphomas
83 were clearly
visible in the Workshop, as half of the submitted
MALT lymphoma cases had been investigated for
genetic aberrations. Three structural genetic aber-
rations, t(11;18)(q21;q21), t(1;14)(q22;q32) and
t(14;18)(q32;q21), are regarded as speciﬁc for MALT
lymphoma and their prevalence has recently been
evaluated in a large series comprising both gastric and
extragastric cases.
45 More recently, a fourth trans-
location, t(3;14)(p14.1;q32), has been described as
occurring in MALT lymphomas.
46 Common to all these
four aberrations is that their occurrence is markedly
inﬂuenced by lymphoma site.
45 The t(11;18)(q21;q21)
is preferentially detected in gastric (24%) and pulmon-
ary tumours (50%) but not in ocular adnexal ⁄ orbital
MALT lymphomas in which the t(14;18)(q32;q21) is
found in 24% of cases. The t(3;14)(p14.1;q32) has
been detected in three of six thyroidal MALT lympho-
mas and in 20% of ocular adnexal ⁄ orbital tumours.
45
The very rare t(1;14)(q22;q32) is largely restricted to
pulmonary and gastric lesions. Numerical aberrations,
such as +3, +12 and +18, may occur isolated or,
except in case of a t(11;18)(q21;q21), in combination
with a structural aberration. All these genetic aberra-
tions can be detected in routinely processed tissue by
ﬂuorescence in situ hybridization (FISH); however, the
t(11;18)(q21;q21) is usually evaluated by reverse
transcriptase (RT)-PCR.
91 Importantly, both tech-
niques work well with routinely processed tissue.
Are MALT lymphoma-associated genetic aberrations
diagnostically helpful? The strong association of the
translocations with MALT lymphoma could be help-
ful in certain diagnostic situations, for instance the
demonstration of the t(11;18) by RT-PCR in case of a
small lung biopsy with a lymphoid inﬁltrate suspicious
but not diagnostic of MALT lymphoma. Similarly, the
close association of trisomies 3 and 18 with MALT
lymphoma may be helpful in doubtful cases. As shown
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very often occur in intestinal, salivary gland and ocular
adnexal tumours. In context with the appropriate
histopathological and immunophenotypic features, the
detection of one of these genetic aberrations would
strongly favour the diagnosis of MALT lymphoma.
Therefore, in the above-mentioned context, the two
techniques, i.e. FISH and RT-PCR, are more powerful
than immunoglobulin gene rearrangement studies
by PCR because they are not only able to detect a
monoclonal process but additionally help to classify the
disease.
So far there is no evidence that any of the above-
mentioned genetic aberrations is of clinical signiﬁcance
in extragastric MALT lymphomas; however, ﬁnal
conclusions have to await the results of larger series.
Clinically, extragastric MALT lymphomas often
involve multiple sites at presentation or recur at distant
MALT sites during the course of the disease.
92 There-
fore, thorough staging after diagnosis is very important.
enteropathy-type t-cell lymphoma
The diagnosis of ETCL may be challenging, particularly
in the case of small endoscopic biopsies and if the
lymphoma component is masked by a heavy inﬂam-
matory inﬁltrate. Refractory coeliac disease frequently
precedes the diagnosis of ETCL.
93 In this scenario
duodenal biopsies show villous atrophy and a marked
increase of cytologically normal, but immunopheno-
typically abnormal intraepithelial lymphocytes (IELs),
usually characterized by loss of CD8. Furthermore, the
IELs are monoclonal by PCR. Multiple ﬂat intestinal
ulcers may develop, known as ulcerative jejunitis,
already containing a few cytologically transformed cells
which may be very hard to detect microscopically. The
accumulation of immunophenotypically abnormal,
monoclonal IELs appears to be the ﬁrst step in the
genesis of ETCL. Patients with refractory coeliac disease
and ⁄ or ulcerative jejunitis are therefore suffering from
a neoplastic T-cell disorder, probably involving most of
the gastrointestinal tract.
93
atypical marginal zone hyperplasia of malt
MALT lymphomas usually arise at sites of acquired
MALT and are uncommon in native MALT such as
tonsil and Peyer’s patches. Malignancy in these indo-
lent lymphomas is often inferred by immunoglobulin
light-chain restriction and in some cases by ‘aberrant’
expression of CD43. A notable exception to this rule
has recently been reported by Attygalle et al.
94 and was
discussed at the Workshop. The authors describe six
children with marginal zone hyperplasia affecting the
tonsil or appendix, characterized by expansion of the
marginal zone by centrocyte-like and transformed cells
heavily spilling into the tonsillar crypt epithelium
mimicking MALT lymphoma. Immunophenotypically,
these cells showed k light-chain restriction and CD43
expression; however, comprehensive molecular studies
convincingly failed to show any evidence of monoclo-
nal immunoglobulin gene rearrangement in any of the
six cases. Clinical follow-up did not show any recur-
rence at a mean follow-up of almost 3 years.
Anaplastic large-cell lymphoma and
its differential diagnosis
Anaplastic large-cell lymphoma is a pleomorphic large
cell lymphoma with strong expression of the activation
antigen CD30 (Ki1) in virtually every cell and frequent
involvement of lymph node sinuses.
95 Anaplastic large-
cell lymphoma occurs predominantly in children and
young adults, but a second peak incidence is seen in
60–80-year-olds.
96 In 40–80% of anaplastic large-cell
lymphomas, dysregulation of the receptor tyrosine
kinase gene ALK
97 on chromosome 2p23 is important
in its pathogenesis. ALK expression correlates with
young age, systemic disease, a cytotoxic epithelial
membrane antigen (EMA)+ phenotype and usually a
good prognosis.
98
Although anaplastic large-cell lymphoma represents
only 2–3% of lymphomas overall, a signiﬁcant number
of cases (approximately 40–65%) have extranodal
disease either at a primary site or as part of a systemic
process.
96,99,100 Affected sites include skin (15–30%),
bone (5–20%), liver (5–10%), lung (5–15%), soft tissue
(10–20%), muscle (< 5%) and rarely (< 1%) gut, testis,
parotid, thyroid, breast, pancreas, oral cavity and
ocular adnexa. As the differential diagnosis of CD30+
Table 5. Frequencies (%) of trisomies 3 and 8 in mucosa-
associated lymphoid tissue lymphomas of different sites
45
n Trisomy 3 Trisomy 18
Stomach 71 11 6
Skin 51 20 4
Salivary gland 42 55 19
Ocular adnexa ⁄ orbit 37 38 14
Intestine 16 75 25
Lung 15 20 7
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neoplasms it is crucial to diagnose anaplastic large-cell
lymphoma accurately, particularly at extranodal sites
where other tumours may be more common. The
determination of the extent of extranodal anaplastic
large-cell lymphoma (primary versus systemic process)
is also critically important, particularly in the skin. In
the EAHP Lymphoma Workshop, anaplastic large-cell
lymphoma was the diagnosis or part of the differential
in eight of the 100 cases submitted. These cases
highlighted potential diagnostic pitfalls related to
ectopic antigen expression, showed ALK expression
does not always correlate with systemic disease and
good prognosis and prompted discussion of whether
ALK– anaplastic large-cell lymphoma is distinct from
peripheral T-cell lymphoma unspeciﬁed.
morphological or immunophenotypic features
that could lead to the wrong diagnosis in
anaplastic large-cell lymphoma
The differential diagnosis of anaplastic large-cell lym-
phoma includes other CD30+ large cell proliferations
such as viral infection, drug reactions, other lymph-
omas (Hodgkin’s lymphoma and B-, T- and NK-cell
lymphomas), carcinoma, melanoma and granulocytic
sarcoma.
101–104 In these other processes, CD30 is
often present in only a subset of cells and the staining
pattern may be weak with a focal or diffuse cyto-
plasmic pattern rather than the strong membrane and
Golgi CD30 expression seen in virtually every cell in
anaplastic large-cell lymphoma. In anaplastic large-
cell lymphoma, the cohesive growth pattern, lack
of leucocyte common antigen (CD45RB) in up to
38%,
105 frequent EMA expression, null phenotype
(10–20% of cases), rare keratin expression (partic-
ularly broad-spectrum antikeratin antibody KL1)
106
make carcinoma a strong consideration, as illustrated
by a Workshop case of a CD30+ large pelvic mass
in a 37-year-old female with all these features. ALK
expression and lack of ultrastructural features of an
epithelial malignancy conﬁrmed anaplastic large-cell
lymphoma (Figure 8).
107 In ALK– anaplastic large-cell
lymphoma with a null phenotype, complete immuno-
phenotyping, clinical staging and ultrastructural
studies may be required to make a deﬁnitive diagno-
sis.
108 In addition, it should be remembered that ALK
expression alone is not diagnostic of anaplastic large-
cell lymphoma, as ALK can be present in other
tumours, principally inﬂammatory myoﬁbroblastic
and other soft tissue tumours, tumours of neural
origin (neuroblastoma, glioblastoma) and a very rare
ALK+ B-cell lymphoma.
73,97,109,110
Expression of myeloid antigens (CD13 and rarely
CD117) as detected by ﬂow cytometry is an uncommon
feature of anaplastic large-cell lymphoma, and can also
be potentially misleading.
111–114 Such a case of a
35-year-old female with a parotid mass was included in
the Workshop. Fine-needle aspiration with ﬂow cytom-
etry revealed expression of HLA-DR and CD13 but a
lack of CD2, CD3, CD4, CD8, suggesting the diagnosis
of chloroma. Excisional biopsy and parafﬁn immuno-
peroxidase studies revealed the cells were CD30+,
EMA+, ALK-1+, and the correct diagnosis of anaplastic
large-cell lymphoma was made. In CD13+ cases, care
must be taken to rule out a myeloid process as CD30
can be expressed in granulocytic sarcoma.
103 Rare
cases of myeloid antigen-positive tumours with features
of anaplastic large-cell lymphoma (CD30+, EMA+,
ALK+), CD56 expression, and a TPM4 (tropomyosin 4)-
ALK fusion have been described.
115
alk expression in anaplastic large-cell
lymphoma as a determinant of systemic
disease and prognosis
As a general rule, ALK+ anaplastic large-cell lymphoma
is associated with systemic disease and a better prog-
nosis, but there are important exceptions.
98,99,116–118
Skin is the most common location of extranodal
anaplastic large-cell lymphoma and a critical site to
determine with certainty if disease is limited to the skin
or secondary to a systemic process. Primary cutaneous
anaplastic large-cell lymphoma is indolent (disease-
related 5-year survival of >90%) compared with skin
involvement in systemic disease (5-year survival of
<45%).
16,119,120 The treatment of primary cutaneous
anaplastic large-cell lymphoma is conservative with
resection with or without irradiation; low-dose metho-
trexate is used in multifocal disease not amenable to
localized therapy. In contrast, systemic anaplastic large-
cell lymphoma requires multiagent chemotherapy. At
the present time,thereare noreliable biologicalmarkers
to distinguish the two types of anaplastic large-cell
lymphoma. Most primary cutaneous anaplastic large-
cell lymphomas are ALK–,
121 and ALK expression in the
skin in the majority of skin lesions indicates systemic
disease.
116 However, as shown in a Workshop case of a
26-year-old male, rare cases of well-documented pri-
mary cutaneous anaplastic large-cell lymphoma are
ALK+ (Figure 8).
122,123 Conversely, it should also be
remembered that ALK negativity in the skin does not
excludesystemicdisease,as20–60%ofanaplasticlarge-
cell lymphomas can be ALK–.
Another Workshop case of primary cutaneous
anaplastic large-cell lymphoma was ALK– but
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Figure 8. a–c, Keratin+ ALK+ anaplastic large-cell lymphoma in a pelvic mass from a 37-year-old female. a, The growth pattern suggests
an epithelial process. b, The large cells strongly express pan keratin (KL1); epithelial membrane antigen is positive and CD45 and T-cell antigens
and T-cell receptor gene rearrangements are negative (not shown). Ultrastructural features are compatible with lymphoma. c, ALK present in
the nucleus and cytoplasm. Case contributed by L. Donner, Temple, TX, USA (B4).
13 d–f, ALK+ primary cutaneous anaplastic large-cell
lymphoma presenting as a 30-mm tender thigh nodule in a 26-year-old male (Images case 89,A1). d, Sheets of large pleomorphic lymphocytes
are present throughout the dermis. Many cells have a hallmark appearance with folded indented nuclei. e, The cells strongly express membrane
and cytoplasmic (Golgi, dot-like) CD30. f, The cells have strong nuclear and cytoplasmic ALK expression. Fluorescence in situ hybridization
studies conﬁrmed translocation of the ALK gene. Careful staging and follow-up at 9 months showed no other evidence of disease. (Case
contributed by B. Kim, Pittsburgh, PA, USA). g–i, ALK+ primary CNS anaplastic large-cell lymphoma in a 27-year-old HIV– male (Images case
90,B9). g, Sheets of dysplastic large lymphocytes diffusely inﬁltrate the brain. h, The tumour cells have cytoplasmic and some nuclear ALK
expression and are CD30+ (not shown). i, CD56 is present in the tumour cells. (Case contributed by Robert F. Bradley and Michael W. Beaty,
Winston Salem, NC, USA.) j–k, ALK– anaplastic large-cell lymphoma arising in the ﬁbrous capsule surrounding a breast implant in a 49-year-old
female (Images case 91,D11). k, Sheets of large tumour cells are present. l, The tumour cells are strongly CD30+ with a membrane and
Golgi pattern of immunoreactivity. (Case contributed by Daphne de Jong, Amsterdam, the Netherlands).
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in systemic anaplastic large-cell lymphoma with
secondary skin involvement rather than in primary
cutaneous anaplastic large-cell lymphoma (67% ver-
sus 32%, respectively),
123 so EMA expression cannot
be used reliably to stage cutaneous anaplastic large-
cell lymphoma. EMA may be expressed in large cells
in 31% of lymphomatoid papulosis, making EMA of
little use in distinguishing lymphomatoid papulosis
Type C from primary cutaneous anaplastic large-cell
lymphoma. If present, EMA would be useful in
distinguishing anaplastic large-cell lymphoma from
other reactive CD30+ cutaneous inﬁltrates (bug bites,
drug reactions, viral infections, etc.). It should be
mentioned that clusterin was initially thought to be
exclusively expressed in systemic anaplastic large-cell
lymphoma,
124 but recent larger studies have docu-
mented clusterin expression in 41–100% of primary
cutaneous anaplastic large-cell lymphomas.
125–127
Careful staging and close clinical follow-up remain
the most reliable methods to conﬁrm a diagnosis of
primary cutaneous disease.
Most studies have shown patients with systemic
ALK+ anaplastic large-cell lymphoma have a fav-
ourable prognosis compared with the ALK–
group.
98,99,117,118 Patients with ALK+ tumours at
extranodal sites, particularly the bone, may not always
have a good prognosis.
128 Other poor prognostic factors
include small cell variant histology and peripheral
blood involvement and CD56 expression.
118,129–131
Primary CNS anaplastic large-cell lymphoma is very
uncommon, being reported in less than 20 cases. ALK+
primary CNS anaplastic large-cell lymphomas (approxi-
mately 50%) have been reported to have a better
prognosis.
132 An unusual feature of primary CNS
anaplastic large-cell lymphoma is the high degree of
involvement of the dura or leptomeninges (69%).
131,132
A CD56+, ALK+, t(2;5)(p23;q35)+, primary brain
anaplastic large-cell lymphoma in a 27-year-old im-
munocompetent male was included in the Workshop
(Figure 8). Despite the ALK+ phenotype, the patient
had an aggressive course possibly related to CD56
expression by the tumour cells. As has been previously
suggested in primary lymphoma of the peripheral
nerve, CD56 (NCAM, neural cell adhesion molecule)
expression may explain localization to the nervous
system through homophilic binding of CD56+ tumour
cells to CD56 on neural cells.
133 It should be mentioned
that ALK is weakly positive in normal glia, neurones
and endothelial cells in the CNS
134 but does not pose a
problem in determining positivity in brain anaplastic
large-cell lymphoma.
132 ALK is expressed in neurobla-
stoma and glioblastoma, but these tumours are CD30–.
how to classify alk anaplastic large-cell
lymphoma
Approximately 20–60% of anaplastic large-cell
lymphomas are ALK–. Due to lack of a deﬁned common
pathogenic mechanism or speciﬁc clinicopathological
features (other than primary cutaneous anaplastic
large-cell lymphoma), haematopathologists have deba-
ted whether the diagnostic criteria for ALK– anaplastic
large-cell lymphoma deﬁne a speciﬁc entity or if ALK–
anaplastic large-cell lymphoma should be included in
peripheral T-cell lymphoma unspeciﬁed. Three ALK–,
CD30+ non-cutaneous T-cell lymphomas were inclu-
ded in the Workshop. Two were difﬁcult to classify. One
was a lung lesion with CD30 expression in a subset of
the cells and an angiocentric growth pattern. The
tumour cells were CD4+, CD5+ but lacked EMA, TIA-1,
CD56 and EBV expression and the diagnosis was a
CD30+ peripheral T-cell lymphoma unspeciﬁed. The
second ALK– anaplastic large-cell lymphoma expressed
CD15 and CD30 and the differential diagnosis was
Hodgkin’s lymphoma versus a CD15+ anaplastic large-
cell lymphoma versus a CD15+, CD30+ peripheral
T-cell lymphoma.
135,136 Whether CD15 expression
excludes a diagnosis of anaplastic large-cell lymphoma
and whether CD15+, CD30+ T-cell lymphomas repre-
sent a speciﬁc entity will be answered when more cases
have been studied.
The third ALK– anaplastic large-cell lymphoma case
was a rare presentation of T-cell anaplastic large-cell
lymphoma arising in the soft tissue around a breast
implant in a 49-year-old female (Figure 8). Anaplastic
large-cell lymphoma rarely presents in the breast as
primary or secondary disease.
137 If the previous
reports, approximately 35% of anaplastic large-cell
lymphomas in the breast have arisen in association
with prosthetic implants
137,138 and anaplastic large-
cell lymphoma represents at least 50% of cases of
lymphoma associated with breast implants.
137 Other
than an interesting hypothesis regarding the relation-
ship of the prosthetic material to immune stimulation
and the development of lymphoma, most of the
discussion in this Workshop case centred around
whether ALK– anaplastic large-cell lymphoma repre-
sents a distinct entity. The remainder of this section will
discuss the case against placing ALK– anaplastic large-
cell lymphoma back into the category peripheral T-cell
lymphoma unspeciﬁed.
Comparative genomic hybridization studies com-
paring ALK– anaplastic large-cell lymphoma and
peripheral T-cell lymphoma unspeciﬁed by Zettl et al.
have shown important genetic differences. Although
peripheral T-cell lymphoma unspeciﬁed and ALK–
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mosomal alterations (such as loss of 6q and 13q)
frequently reported for other T- and B-cell non-
Hodgkin lymphoma (NHL),
139 the tumours show
signiﬁcant differences. Loss of 9p21-pter (31% in
peripheral T-cell lymphoma unspeciﬁed and 0% in
anaplastic large-cell lymphoma, Fisher’s P ¼ 0.0244)
and 5q21 (33% in peripheral T-cell lymphoma unspec-
iﬁed versus 0% in anaplastic large-cell lymphoma,
Fisher’s P ¼ 0.0126) is signiﬁcantly more common in
peripheral T-cell lymphoma unspeciﬁed. There is a
trend for ALK– anaplastic large-cell lymphoma to have
gains of chromosome 1q (46% versus 17%, Fisher’s
P ¼ 0.0577). In addition, these data show a trend for
both peripheral T-cell lymphoma unspeciﬁed and ALK-
anaplastic large-cell lymphoma to have distinct genetic
differences when compared with ETCL, T-prolympho-
cytic leukaemia and adult T-cell leukaemia ⁄ lym-
phoma. The degree of genetic instability varied
between ALK– and ALK+ anaplastic large-cell lym-
phoma and peripheral T-cell lymphoma unspeciﬁed,
with the greatest in the latter. Losses of 5q and 12q also
appear to segregate peripheral T-cell lymphoma
unspeciﬁed from other well-deﬁned T-cell lymphomas.
A recent paper using FISH for the 2p23 locus showed
extra copies of chromosome 2p23 in all ﬁve samples
from four patients with ALK– anaplastic large-cell
lymphoma and in ﬁve of seven primary cutaneous
anaplastic large-cell lymphomas, but in none of six
ALK+ anaplastic large-cell lymphomas.
140 Zettl et al.
found imbalances in chromosome 2 in ﬁve (26%) of
nodal ⁄ systemic anaplastic large-cell lymphomas (one
ALK+, four ALK–) and no primary cutaneous anaplas-
tic large-cell lymphoma. Zettl et al. also reported
solitary ampliﬁcations of 2cen-p22 or imbalances
of chromosome 2 were present in 15 ⁄ 42 (31%) of
peripheral T-cell lymphoma-NOS. Extra copies of
chromosome 2 are not uncommon in lymphoma and
have been reported in B- and T-cell lymphoma and
Hodgkin’s lymphoma in the Mitelman Database of
Chromosome Aberrations in Cancer.
141
A defect in T-cell receptor (TCR) ab protein expres-
sion (based on immunohistochemical detection using
the antibody bF-1) has been identiﬁed in >90% of
ALK+ and ALK– anaplastic large-cell lymphomas
142
compared with loss of bF-1 expression in only approxi-
mately 10% of peripheral T-cell lymphoma unspeciﬁed
and no angioimmunoblastic T-cell lymphomas (AILT).
Ninety-six percent of ALK+ and 40% of ALK– ana-
plastic large-cell lymphomas also lacked expression of
the CD3 antigen, compared with 29% of peripheral
T-cell lymphomas NOS and 20% of AILT. CD3 mole-
cules are associated with the TCR protein and trans-
duce the signal of TCR engagement to ZAP-70, a
tyrosine kinase that integrates cognate and costimula-
tory signals for downstream signalling. As further
evidence of a defect in TCR signalling, ZAP-70 is lost in
anaplastic large-cell lymphoma compared with other
T-cell lymphomas.
143 Overall, ZAP-70 is detected in
25–30% of anaplastic large-cell lymphomas (8–25% of
ALK+ and 20–41% ALK–) versus 59–74% peripheral
T-cell lymphomas NOS and 29–57% of primary
cutaneous (PC) anaplastic large-cell lymphomas.
143,144
Virtually all (82–100%) systemic anaplastic large-
cell lymphomas, including ALK+ and ALK– cases, and
41–100% of PC anaplastic large-cell lymphomas
express clusterin, a ubiquitous glycoprotein encoded
by a gene on chromosome 8p21. Clusterin has many
proposed functions including complement regulation,
cell aggregation, lipid transport and response to cell
injury or stress. Clusterin is expressed in a Golgi-
associated pattern in anaplastic large-cell lymph-
oma.
125–127 In contrast, clusterin is present in only
3.5% of peripheral T-cell lymphoma unspeciﬁed cases
from three series
124,125,127 and only 13% of other
T-cell neoplasms were positive and usually showed a
more diffuse cytoplasmic staining rather than the more
distinct Golgi pattern of reactivity seen in anaplastic
large-cell lymphoma.
125,127
Recent microarray analysis of ALK+ and ALK–
anaplastic large-cell lymphoma (including primary
cutaneous anaplastic large-cell lymphoma) has shown
ALK+ compared with ALK– anaplastic large-cell lym-
phoma over-expresses genes encoding signal transduc-
tion molecules (SYK, LYN, CDC37) and underexpresses
transcription factor genes (including HOXC6 and HOX
A3).
145 Both groups highly expressed kinase genes
(LCK, protein kinase C, vav2 and NKIAMRE) and anti-
apoptotic molecules, suggesting overlap in pathogene-
sis; a comparison with peripheral T-cell lymphoma
unspeciﬁed was not performed in this study.
In summary, since the original description there
have been difﬁculties in diagnosis and classiﬁcation of
anaplastic large-cell lymphoma. Frequent involvement
of extranodal sites, the promiscuity of CD30, expression
of EMA with frequent lack of lymphocyte common
antigen (LCA) and, as cases in this session pointed out,
rare keratin and myeloid antigen expression contribute
to the potential misdiagnosis. Recognition of the t(2;5)
and abnormal expression of ALK in lymphoid tissue
have further clariﬁed our understanding of anaplastic
large-cell lymphoma and helped in its diagnosis,
particularly at extranodal sites or where other antigens
may be expressed. ALK expression is usually associated
with systemic disease and a better prognosis, but there
are important exceptions. ALK expression can rarely be
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skin; there is currently no substitute for careful staging
and follow-up. In ALK+ anaplastic large-cell lym-
phoma other factors such as CD56 may indicate a poor
prognosis.
Lastly, the classiﬁcation of ALK– anaplastic large-cell
lymphoma is controversial. Current genetic and biolo-
gical features provide evidence that ALK– anaplastic
large-cell lymphoma is more closely related to ALK+
anaplastic large-cell lymphoma than peripheral T-cell
lymphoma unspeciﬁed and strongly support inclusion
of ALK– CD30+ lymphomas with anaplastic large-cell
lymphoma in future lymphoma classiﬁcation. How-
ever, to make a diagnosis of ALK– anaplastic large-cell
lymphoma there must be strict adherence to charac-
teristic cytology (a large cell predominant population
with abundant cytoplasm and pleomorphic, embryo or
hallmark nuclei or wreath-like giant cells) and strong
CD30 expression with a membrane and Golgi distribu-
tion in virtually every cell. In lymph nodes, some
involvement of sinuses should be seen. Fortunately,
most small cell predominant or lymphohistiocytic
variants of anaplastic large-cell lymphoma are ALK+,
as a diagnosis of ALK– anaplastic large-cell lymphoma
with variant histology would be particularly difﬁcult;
large CD30+ hallmark type cells must be present with
a preferential distribution of the CD30+ large cells
around blood vessels.
131 In ALK– anaplastic large-cell
lymphoma with a null phenotype (and genotype),
immunostains to exclude other tumours such as
Hodgkin lymphoma (HL), carcinoma and acute leuk-
aemia must be performed (Table 6).
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